|
|
Volumn 112, Issue 3 I, 2003, Pages 669-670
|
|
Congress, the FDA, and the fair development of new medications for children
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIHISTAMINIC AGENT;
ANTIRETROVIRUS AGENT;
DIDANOSINE;
EFAVIRENZ;
INDINAVIR;
LAMIVUDINE;
LOPINAVIR;
LOPINAVIR PLUS RITONAVIR;
NELFINAVIR;
NEVIRAPINE;
RITONAVIR;
ZIDOVUDINE;
CHILD CARE;
CLINICAL RESEARCH;
DRUG LABELING;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NOTE;
ORGANIZATION;
PRIORITY JOURNAL;
ADULT;
CHILD;
CONGRESSES;
DRUG APPROVAL;
DRUG DESIGN;
DRUG INDUSTRY;
DRUG LABELING;
HUMANS;
LEGISLATION, DRUG;
ORPHAN DRUG PRODUCTION;
PHARMACEUTICAL PREPARATIONS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0041336973
PISSN: 00314005
EISSN: None
Source Type: Journal
DOI: 10.1542/peds.112.3.669 Document Type: Note |
|
Times cited : (15)
|
|
References (2)
|
